As­traZeneca, Sanofi's RSV an­ti­body set for FDA ad­comm on Thurs­day

The FDA’s An­timi­cro­bial Drugs Ad­vi­so­ry Com­mit­tee is set to meet Thurs­day to dis­cuss As­traZeneca and Sanofi’s RSV an­ti­body nir­se­vimab, mak­ing it the third ther­a­py aimed at res­pi­ra­to­ry syn­cy­tial virus to inch clos­er to ap­proval this year.

An­oth­er com­mit­tee, the FDA’s Vac­cines and Re­lat­ed Bi­o­log­i­cal Prod­ucts Ad­vi­so­ry Com­mit­tee (VRB­PAC), re­cent­ly as­sessed Pfiz­er’s RSV vac­cine and GSK’s RSV vac­cine, both of which are for old­er adults and re­ceived FDA ap­proval in May.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.